chevron_leftBack
As of 16 June 2026, Exicure, Inc. has a market cap of $21.1M USD, ranking #36741 globally and #4972 in the United States.
It ranks #3301 in the Healthcare sector, and #643 in the Biotechnology industry.
Key Stats
Market Cap
$21.1MUSD
Enterprise Value
$18.55MUSD
EBITDA (TTM)
-$9.88MUSD
Net Income (TTM)
-$4.95MUSD
PB Ratio
5.6
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Jungsoo Kim
open_in_new
Employees
8
Founded
2011
Website
exicuretx.com
open_in_new
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -4.6% | -10% | -23% | -19% | -26% | -69% |
News
Loading...
XCUR Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
XCUR
Exicure Inc
ISIN: US30205M3097
Shares Out.:
Shares Outstanding:
6.374M1
Shares Float:
4.206M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
3.31 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Exicure, Inc.
Exicure, Inc. does not have significant operations. Previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
865K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
758K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
131K%
|
-
|
|
NYSE: IQV
|
$26.3B
125K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
119K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
86K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.89B
227K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$45.02B
213K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.64B
202K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.17B
200K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.23B
134K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
122K%
|
-
|
chevron_leftBack